Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Proof of Principle Program - Phase I

McMaster University

$160,000.00

Characterization of small molecule sensitizers to chemotherapy

EF 2011-12

Résumé
Despite recent advances in diagnosis and treatment breast cancer remains a leading cause of cancer death in women worldwide. Current anticancer chemotherapies fail to provide long-term remission for the majority of breast cancer patients, especially those with advanced disease. We sought to identify chemicals and preferably existing drugs that might improve the efficacy of chemotherapies commonly used to treat breast cancer. Our approach yielded a drug known as adiphenine, a smooth muscle relaxant, which was developed decades ago to treat urinary, biliary and intestinal spasms. Adiphenine has no apparent anticancer activity on its own but dramatically increases the activity of two chemotherapies, Adriamycin and Taxotere, which are commonly used in combination to treat breast cancer patients with biologically aggressive disease. Indeed experiments with human breast tumor cell lines in tissue culture revealed that the dose of Adriamycin and Taxotere required to kill these cells could be reduced when adiphenine is provided with these chemotherapeutic agents. Interestingly adiphenine inhibits the activity of nicotinic acetylcholine receptors, which have recently been reported to be overexpressed in human breast tumors. The latter receptors are also overexpressed in patients with other malignancies, especially lung cancer. The pharmacological properties of adiphenine are well known and hence it could be readily repurposed as a chemo-sensitizing agent. We propose to test the chemo-sensitizing activity of adiphenine in mouse models of breast cancer. The results of this pre-clinical study should set the stage for a phase I clinical trial in breast cancer patients with aggressive disease.
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
240746
Name
Hassell John A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Characterization of small molecule sensitizers to chemotherapy
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$160,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Chemo-Sensitizer; Chemotherapy
Abstract
Despite recent advances in diagnosis and treatment breast cancer remains a leading cause of cancer death in women worldwide. Current anticancer chemotherapies fail to provide long-term remission for the majority of breast cancer patients, especially those with advanced disease. We sought to identify chemicals and preferably existing drugs that might improve the efficacy of chemotherapies commonly used to treat breast cancer. Our approach yielded a drug known as adiphenine, a smooth muscle relaxant, which was developed decades ago to treat urinary, biliary and intestinal spasms. Adiphenine has no apparent anticancer activity on its own but dramatically increases the activity of two chemotherapies, Adriamycin and Taxotere, which are commonly used in combination to treat breast cancer patients with biologically aggressive disease. Indeed experiments with human breast tumor cell lines in tissue culture revealed that the dose of Adriamycin and Taxotere required to kill these cells could be reduced when adiphenine is provided with these chemotherapeutic agents. Interestingly adiphenine inhibits the activity of nicotinic acetylcholine receptors, which have recently been reported to be overexpressed in human breast tumors. The latter receptors are also overexpressed in patients with other malignancies, especially lung cancer. The pharmacological properties of adiphenine are well known and hence it could be readily repurposed as a chemo-sensitizing agent. We propose to test the chemo-sensitizing activity of adiphenine in mouse models of breast cancer. The results of this pre-clinical study should set the stage for a phase I clinical trial in breast cancer patients with aggressive disease.
Competitiondate
201109
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hassell, John A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $160,000~ $0~